Zimulti

Description:

Zimulti (RIMONABANT) is an appetite suppressant diet pill. Zimulti is used in the treatment of obesity and related conditions.

Product Description

Common uses

Zimulti is used complementary to diet and exercise to treat obese or overweight patients who suffer from Type 2 diabetes and abnormal levels of fat in the blood. It can also prevent the risk of cardiovascular disease.

Directions

The usual dose is one 20 mg tablet to be taken once daily in the morning before breakfast. Swallow the tablet whole.

Cautions

It is advisable to consult a doctor before taking Zimulti and adhere to the prescribed dosage to attain the expected results. Zimulti should not be taken by pregnant woman since it may cause birth defects in an unborn baby. Zimulti should not also be used by lactating mothers. Though not clinically proved, there is possibility that this diet pill may be passed into breast milk. Zimulti is metabolized by the liver, so it is recommended that patients with moderate hepatic impairment should consult their healthcare provider before using the drug.

Possible side effects

Side effects in the trial on Zimulti in obesity were vomiting and nausea, forcing about 19 percent of patients to leave the trial versus 13 percent of those who took placebo.

Clinical studies found that 26 percent of people taking Zimulti reported psychiatric symptoms, including anxiety, insomnia, panic attacks as well as increases in aggression and agitation compared to patients given a placebo.

Zimulti has also been shown to cause increased suicidal tendencies and other depressive symptoms.

Additional information

It is advisable to consult a doctor before taking Zimulti and adhere to the prescribed dosage to attain the expected results. Zimulti should not be taken by pregnant woman since it may cause birth defects in an unborn baby. Zimulti should not also be used by lactating mothers. Though not clinically proved, there is possibility that this diet pill may be passed into breast milk. Zimulti is metabolized by the liver, so it is recommended that patients with moderate hepatic impairment should consult their healthcare provider before using the drug.